Argenx (ARGX)
(Delayed Data from NSDQ)
$457.68 USD
+21.26 (4.87%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $457.96 +0.28 (0.06%) 6:28 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$457.68 USD
+21.26 (4.87%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $457.96 +0.28 (0.06%) 6:28 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
by Zacks Equity Research
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
by Zacks Equity Research
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
GSK Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on Viking Therapeutics' (VKTX) pipeline updates when it reports first-quarter earnings results.
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
by Zacks Equity Research
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
by Zacks Equity Research
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
by Zacks Equity Research
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?
by Zacks Equity Research
Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect increasing patient days and admissions.
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.
How Argenx (ARGX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
by Zacks Equity Research
Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study
by Zacks Equity Research
argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.